Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trebananib

Drug Profile

Trebananib

Alternative Names: 20060439; AMG-386

Latest Information Update: 26 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Dana-Farber Cancer Institute; Gynecologic Oncology Group; Merck Sharp & Dohme; National Cancer Institute (USA); Quantum Leap Healthcare Collaborative; Roswell Park Cancer Institute; Takeda
  • Class Antibodies; Antineoplastics; Peptides; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-1 inhibitors; Angiopoietin-2 inhibitors; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma

Most Recent Events

  • 26 Jul 2019 Amgen completes a phase II trial in Renal cell cancer (NCT00853372)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top